Национальная контактная точка "Здравоохранение"Comment le patient cialis pharmacie cialis est-il informé?
The Horizon Health, demographic change and well-being call is open with 11 topics that require to use an specific template if you carry out a clinical study (http://ec.europa.eu/research/participants/data/ref/h2020/other/legal/tem...).
European Comission introduced a new feature on the Participant Portal. It now offers the possibility to look for partners directly in the context of individual call topics (open and forthcoming).
Potential applicants can access the list of existing partner search requests for a given topic via the individual call topic pages (https://ec.europa.eu/research/participants/portal/desktop/en/opportuniti...).
In the current issue of Info-letter you can find information on open international calls:
- Horizon 2020 Work Programme 2018-2020
- EU-Russia Coordinated Call on infectious diseses
- Joint call of the RFBR and Austrian Science Fund (deadline – February 1, 2018)
- Joint Russian-French initiative research projects competition of the RFBR and Centre National de la Recherche Scientifique (deadline – February 13, 2018)
- Joint call of the RFBR and German Research Foundation (DFG) (deadline - March 1, 2018)
The Health Open Info Day took place on 8 December.
The Work Programme for Horizon 2020's Societal Challenge 1: Health, Demographic Change and Wellbeing over the next 3 years (2018-2020) was presented. Participants were informed about the topics, deadlines and process of the next calls for proposals.
The Innovative Medicines Initiative has now launched IMI2 – Call 13.
§ Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
§ Genome-environment interactions in inflammatory skin disease
§ The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
§ Mitochondrial dysfunction in neurodegeneration
§ Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative
